Kan Chen
陈侃
According to elsewhere's entity records, Kan Chen is a partner at Qiming Venture Partners and previously a team leader at Hengrui Medicine . Beyond that, elsewhere's corpus has no articles profiling him — no coverage of his deals, focus areas, or career history in the current material.
AI-generated — may contain errors, please verify.
Coverage
Qiming Star | Immune-Mediated Disease Leader Attovia Therapeutics Debuts on Nasdaq | Bilingual
Focused on developing next-generation biotherapeutics for immune-mediated diseases with significant unmet clinical needs.
Qiming Star | MedLinkTherapeutics' Xue Tongtong: In ADC's Blue Ocean Era, the Pragmatic Will Prevail
Yili Biotech Could Become the Next Big Pharma
Qiming View | Qiming Venture Partners' Kan Chen: Leading Two Consecutive Rounds for Ticen Biotech, Firmly Committed to Cutting-Edge Medical Innovation
Qiming Venture Partners remains steadfast in its focus on addressing unmet clinical needs and consistently pursues cutting-edge healthcare innovations with global competitiveness.
Qiming Venture Partners Portfolio Company Tiachen Biologics, a Leader in Allergy and Autoimmune Innovative Drugs in China, Successfully Lists on Hong Kong Exchanges and Clearing Limited
In 2024, Qiming Venture Partners led TianChen Bio's Series B2 round, and then co-led the company's Series C round in 2025.
Qiming Venture Partners' Kan Chen: NewCo Model Profoundly Impacts Global Value of Chinese Innovative Drugs
This isn't just a successful investment case — it more profoundly reveals the path by which China's pharmaceutical innovation is being revalued.
Vivatides Therapeutics Oversubscribes $54 Million Series A, Co-Led by Qiming Venture Partners
An international innovative biopharmaceutical company focused on the R&D of extrahepatic-targeted small nucleic acid drugs
Qiming Venture Partners and Its Investors Named to Diyixinsheng's 2025 China Investment Institutions and Individuals Rankings
Designed to unearth a genuine "founder's guide to fundraising, an LP's investment reference."
Qiming View | Qiming Venture Partners' Kan Chen: Innovative Drug Primary Market Recovers, Bullish on Domestic FIC Innovative Drugs
Qiming Venture Partners will continue to stand by exceptional companies with a long-term mindset, helping them navigate cycles and expand globally.
Qiming Venture Partners and Six Team Members Honored on LP CLUB 2025 Annual Rankings
Recognizing outstanding organizations and individuals who have forged ahead with remarkable achievements over the past year, setting new benchmarks for industry development.
Five AI IPOs in Seven Months, Qiming Venture Partners: Investing in AI Is the Biggest Certainty for China Over the Next Two Decades
Thirteen years, over 100 portfolio companies, covering the full AI industry chain.
Qiming Venture Partners Investors Land on ChinaVenture 2025 Investor Rankings
A bellwether for China's equity investment industry and a key reference for major institutional LPs when making allocation decisions.
Qiming Venture Partners and Its Investors Win Seven Awards Including Top 10 Best IPO Investment Institutions of 2025 by IPO Zao Zhi Dao
We hope to highlight investment firms that were bolder in their early-stage bets and backed projects that exerted greater influence on their industries and the market at large.
Qiming Venture Partners Portfolio Company Insilico Medicine Successfully Lists on Hong Kong Exchanges and Clearing Limited
In 2019, Qiming Venture Partners led Insilico Medicine's Series B financing and continued to back the company through its Series C and D rounds. Prior to the IPO, Qiming Venture Partners held approximately 7% of Insilico Medicine's shares, making it one of the company's most important institutional investors.
Qiming Venture Partners' Kan Chen: Investing in Insilico Medicine four years before OpenAI went mainstream, AIDD platform has broad prospects
After completing its investment in Insilico Medicine, Qiming Venture Partners provided the company with sustained support and substantial assistance.
Qiming Venture Partners Earns Five Spots on 2025 Forbes China Midas List
Identify and recognize 100 investors who have delivered strong performance over the past five years.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 43, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 40, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Yangli Pharma closes nine-figure RMB Series B round led by Qiming Venture Partners
Focused on developing first-in-class and best-in-class Class 1 innovative drugs with global intellectual property rights, with a focus on oncology and chronic disease therapeutics.
Morning Star | Weitao Biotech Raises Over 100 Million Yuan in Angel Round Led by Qiming Venture Partners
Innovative companies in the global in vivo cell therapy space
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 39, 2025
Staying with you to mark milestone moments for Qiming Venture Partners' portfolio companies
Qiming Healthcare Partnering Day 2025 Successfully Held in Shanghai, Fostering Partnerships Between Global Pharma Giants and Chinese Biotech Startups
This marks the fourth consecutive year that Qiming Venture Partners has hosted this event, which to date has facilitated hundreds of one-on-one meetings for over a hundred leading global pharmaceutical and investment companies, laying a solid foundation for expanding the scope and elevating the level of collaboration between enterprises.
Qiming Star | Changsen Pharma Raises Hundreds of Millions of Yuan in Series B+ Funding to Accelerate Clinical Research and Global Expansion of Core Pipeline
Changsen Pharma is dedicated to independently developing first-in-class, best-in-class innovative drugs with global intellectual property rights to address unmet clinical needs.
Qiming Portfolio Company Yanyin Technology Partners with HEC Pharm on Strategic AI Collaboration
The two parties will engage in in-depth collaboration on AI agent R&D, using the AI translation agent project as a starting point to develop solutions covering core scenarios including experimental design and IND filing, as well as AI laboratory automation robotics. Together, they will explore the deep application of AI technology across the full drug discovery and development pipeline, accelerating the globalization strategy of East Sunshine Pharmaceutical.
Qiming Venture Partners and Multiple Portfolio Companies Named to Jazzyear's 2024-2025 China Tech Industry Investment Rankings
The list aims to recognize outstanding investment institutions, investors, and science and technology innovation enterprises that have made significant contributions to the development of China's tech industry.
Qiming Venture Partners Weekly | Portfolio Company Updates Vol. 31, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Weekly | Portfolio Companies Funding and Updates Vol. 29, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Minghui Pharmaceutical Raises $131M in Pre-IPO Round Co-Led by Qiming Venture Partners
Minghui Pharmaceutical is a late-stage biopharmaceutical company focused on oncology and autoimmune diseases.
Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners
Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.
Qiming Weekly | Qiming Venture Partners Portfolio Companies: Funding and Updates Vol. 28, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads
Emergent Tide is built on original research from the Tsinghua University School of Medicine team in the field of humoral immunity, developing novel therapeutics for inflammatory and autoimmune diseases against a first-in-class global target, addressing core challenges in the field and significant unmet clinical needs.
Qiming Weekly | Qiming Venture Partners Portfolio Companies Funding and Updates Vol. 23, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Portfolio Companies YanYin Technology and ZhuanMa Bio Launch China's First CRISPR Gene Design Tool
The two parties will jointly develop a next-generation CRISPR design application platform, deeply integrating Zuanma Biotech's cutting-edge gene editing technology with YanYin AI's cloud-based R&D platform. This collaboration will deliver unprecedented convenience, precision, and efficiency to CRISPR gene editing users worldwide, dramatically streamlining the design and analysis workflows for gene editing experiments.
Qiming Venture Partners-backed Sinogen Pharma advises Genrix Bio on over $700M BCMA/CD3 out-license deal with Cullinan
SinoKin Pharmaceutical served as the business development advisor to Zhixiang Jintai, providing end-to-end commercial services that included evaluating different partnership models with several foreign biopharmaceutical companies and investment institutions, helping Zhixiang Jintai secure multiple investment agreements.
Qiming Star | Tianchen Biotech Raises Over 200 Million Yuan in Series C, Co-Led by Qiming Venture Partners
TianChen Bio is committed to setting the industry benchmark in allergic diseases and complement-mediated diseases, continuously driving treatment innovation to deliver breakthrough therapies with greater clinical value and accessibility for patients worldwide.
Qiming Venture Partners' 16th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
China's high-quality companies have reached a valuation level that's become genuinely attractive.
Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident
In the AI era, drug discovery is taking on the characteristics of data-driven, high-throughput, automated, and intelligent processes, potentially improving success rates and lowering costs. In the near term, the necessity of experimental validation will remain unchanged; over the long run, the foundational theories of biology will stay stable. This balance between transformation and continuity is reshaping the entire landscape of pharmaceutical R&D.
Qiming Venture Partners and Over 10 Portfolio Companies Named to 2024 China Healthcare Industry Investment Glory List
The list not only recognizes outstanding investment institutions, investors, and companies, but also provides directional guidance for the evolution of industry investment logic, redefines the value standards for talent, and brings positive momentum to the industrial ecosystem.
Qiming Venture Partners and 50+ portfolio companies named to 2025 Future Healthcare 100 list
These rankings and reports aim to document the year's industry breakthroughs and reveal the growth patterns of listed companies and evolving industry trends, offering a reference for healthcare enterprises and entrepreneurs.
Qiming Venture Partners-Backed Belief BioMed Announces Approval of China's First Hemophilia B Gene Therapy Drug Xinjining®
As China's first independently developed gene therapy for hemophilia B, Xinjiuning® will offer patients a completely new treatment option, with the potential to free them from a lifetime of frequent intravenous injections and help them return to a life without constraints.
Qiming Perspective | Qiming Venture Partners' Kan Chen: China's Innovative Drug Exports Hit Record Highs, Where Is Innovative Drug Investment Heading?
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
Qiming Venture Partners and Four Portfolio Companies Named to PharmCube TOP15 Annual Awards
The awards aim to establish benchmark investment institutions and enterprises with annual bellwether significance for China's pharmaceutical industry.
What Would Qiming Venture Partners Look Like Without Nisa Leung?
Together, we welcome a new era.
Qiming Venture Partners' Kan Chen: There's an Optimal Path for Chinese Innovative Drugs Going Global
Move beyond single concepts and invest in "global biotech."
Linear Capital's angel-round lead portfolio company, digital microfluidics technology platform Aoxu Technology, has completed a nearly RMB 100 million Series A funding round, with existing investor Linear Capital continuing to increase its support.
Recently, Foshan Aces Bio-Tech Co., Ltd. (hereinafter referred to as "Aces") announced the completion of a nearly RMB 100 million Series A financing round. **The round was led by Luxin Venture Capital, with existing shareholders Qiming Venture Partners, Linear Capital, and Tongchuang Weiyue continuing to increase their stakes.** WinX Capital served as the exclusive financial advisor for the third consecutive round.
On the first day of August, we spoke with 23 investors about "confidence."
And, what are the things that are hard but right, and what are the things that are hard but wrong.
MaHui | Source Code Capital's Xingchen Zhang Named to Cyzone's 40 Under 40 Investors List
"Finding tech founders full of conviction"
